Seattle Genetics, Inc. (NASDAQ:SGEN) Files An 8-K Other Events
Item8.01 Other Events.
On June26, 2017, Seattle Genetics, Inc. (the Company) issued a
press release announcing top-line results from the phase 3
ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab
vedotin) as part of a frontline combination chemotherapy regimen
in patients with previously untreated advanced classical Hodgkin
lymphoma.
A detailed description of these top-line results is contained in
the Companys press release dated June26, 2017 which is attached
as Exhibit 99.1 to this current report and is incorporated herein
by reference.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release of Seattle Genetics, Inc. dated June26, 2017 |
SEATTLE GENETICS INC /WA ExhibitEX-99.1 2 d401403dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma -Randomized Phase 3 Clinical Trial with ADCETRIS Met Primary Endpoint,…To view the full exhibit click here About Seattle Genetics, Inc. (NASDAQ:SGEN)
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.